This study evaluates a monoclonal antibody targeting pyroglutamate-modified Aβ (pGlu3-Aβ), demonstrating reduced amyloid plaque load, enhanced microglial engagement, and preserved synaptic integrity in Alzheimer’s disease models.
pGlu3-Aβ immunotherapy reduces plaque load, activates microglia, and protects synapses, suggesting therapeutic potential in AD.
Transgenic hAPP mouse crossed with genOway’s Cx3cr1-CreERT2-tdTomato line for microglial lineage tracing and activation analysis.
Alzheimer’s disease, Neuroinflammation, Microglial activation, Immunotherapy
Humanized APP model, Inducible CreERT2, tdTomato reporter, Microglial tracing, Knockin at endogenous Cx3cr1 locus
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
